EMA Authorised: Icatibant Accord (icatibant acetate) — Accord Healthcare S.L.U.

View source ↗

Summary

The EMA authorised Icatibant Accord (icatibant acetate) for hereditary angioedema, with Accord Healthcare S.L.U. as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Icatibant Accord (icatibant acetate)

Snippet

Status: Authorised. Therapeutic area: Angioedemas, Hereditary. MAH: Accord Healthcare S.L.U.. Decision date: 19/03/2026